10 Reasons Why Kresladi™ Must Be Approved Now

The clock is ticking—lives are on the line. After more than two years in the Food and Drug Administration (FDA) hands, Rocket Pharmaceuticals’ Kresladi™ (marnetegragene autotemcel, marne-cel) still awaits full approval. This gene therapy isn’t just another drug. It’s a scientific triumph—a one-time, curative treatment for a devastating, fatal childhood disease known as Leukocyte Adhesion Deficiency type I (LAD-I).